CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS
January 11 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, today announced it has signed
a Non-Clinical Evaluation Agreement (NCEA) with the National
Institute of Allergy and Infectious Diseases (NIAID) to evaluate
the potential of CB5064 Analogs for the treatment of COVID-19
associated Acute Respiratory Distress Syndrome (ARDS). The company
is developing its CB5064 Analogs for potential treatment of ARDS,
including COVID-19 associated ARDS. This program has shown positive
results in models of acute lung injury, which included reduced
levels of fluid accumulation, neutrophil infiltration, and cytokine
secretion.
CohBar, Inc. will be utilizing the non-clinical and pre-clinical
services program offered by the National Institute of Allergy and
Infectious Diseases. The NIAID will be responsible for any study
conducted under the NCEA. Under the agreement, NIAID will be
provided with CohBar's CB5064 Analogs to test in preclinical models
of COVID-19, such as the golden Syrian hamster SARS-CoV-2 model.
This model has been used in the assessment of other COVID-19
therapeutics and demonstrates clinical features, viral kinetics,
histopathological changes, and immune responses similar to mild to
moderate disease seen in human COVID-19 patients.i
Previously, CohBar submitted its CB5064 Analog program to
Accelerating COVID-19 Therapeutic Interventions and Vaccines
(ACTIV), a public-private partnership led by the National
Institutes of Health (NIH) and coordinated by the Foundation for
the National Institutes of Health (FNIH) to develop a research
strategy for prioritizing and speeding development of the most
promising COVID-19 vaccines and treatments. Discussion with NIAID
was initiated following review of the program by ACTIV/FNIH.
“We are pleased to collaborate with NIAID to provide further
evaluation of our CB5064 Analogs in a model of COVID-19 ARDS,”
stated Dr. Kenneth Cundy, CohBar’s Chief Scientific Officer.
“CohBar’s mitochondrial based therapeutics may generate entirely
new approaches to diseases, which we believe complements the
pioneering work being conducted by NIAID. We look forward to
working with NIAID on this research program.”
A division of the National Institutes of Health (NIH), NIAID
conducts and supports basic and applied research to better
understand, treat, and ultimately prevent infectious, immunologic,
and allergic diseases.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the
potential to regulate key processes
in multiple systems and organs in the body. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases because of
the underlying impact of mitochondrial dysfunction. The company’s
lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b
clinical trial for NASH and obesity. In addition, CohBar has
four preclinical programs: CB5138 Analogs for fibrotic
diseases, CB5064 Analogs for COVID-19 associated ARDS, CB5046
Analogs for CXCR4-related cancer and orphan diseases, and MBT3
Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking
statements which are not historical facts within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and other future
conditions. In some cases you can identify these statements by
forward-looking words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “should,” “would,”
“project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to statements regarding anticipated outcomes of research
and clinical trials for our mitochondria based therapeutic (MBT)
candidates; expectations regarding the anticipated outcomes of
non-clinical and pre-clinical services program for our MBT
candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies,
including but not limited to in the treatment of IPF and COVID-19
associated ARDS. You are cautioned that such statements are not
guarantees of future performance and that actual results or
developments may differ materially from those set forth in these
forward-looking statements. Factors that could cause actual results
to differ materially from these forward-looking statements include:
our ability to successfully advance drug discovery and development
programs and collaborations, including the delay or termination of
ongoing clinical trials; our possible inability to mitigate the
prevalence and/or persistence of the injection site reactions,
receipt of unfavorable feedback from regulators regarding the
safety or tolerability of CB4211 or the possibility of other
developments affecting the viability of CB4211 as a clinical
candidate or its commercial potential; results that are different
from earlier data results including less favorable than and that
may not support further clinical development; our ability to raise
additional capital when necessary to continue our operations; our
ability to recruit and retain key management and scientific
personnel; the risk that our intellectual property may not be
adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website,
and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of
future performance and that our actual results may differ
materially from those set forth in the forward-looking statements.
The forward-looking statements and other information contained in
this news release are made as of the date hereof and CohBar does
not undertake any obligation to update publicly or revise any
forward-looking statements or information, whether as a result of
new information, future events or otherwise, unless so required by
applicable securities laws. Nothing herein shall constitute an
offer to sell or the solicitation of an offer to buy any
securities.
i Hewitt, Judith A., et al. “ACTIVating Resources for the
COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics.”
Cell Host & Microbe, 16 Sept. 2020, pp. 646–659.,
doi:https://doi.org/10.1016/j.chom.2020.09.016.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
Media:Nancy ThompsonVorticom, Inc.(212)
532-2208Nancyt@vorticom.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024